Valion Bio Inc. (VBIO)
NASDAQ: VBIOHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VBIO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.04M
- EPS (TTM)
- -$177.91
- Dividend yield
- None
- 52-week range
- 0.472 – 67.50
- Day range
- 0.48 – 0.5467
- Volume / Avg
- 135.20K / 1.78M
- Beta
- —
- Shares outstanding
- 2.16M
52-week range
VBIO stock today
On Nov 20, VBIO ended the session at $0.4806, shedding $0.0593 (10.98%), versus the S&P 500's 3.70% decline. Trading was light, with 135.20K shares changing hands, about 8% of the average daily volume. At this level, VBIO sits near the bottom of its 52-week range of $0.472 to $67.50: 99.3% below the high and 1.8% above the low.
Valion Bio has posted a net loss over the last twelve months (EPS of -$177.91), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Valion Bio
Company profileValion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CEO
- Mr. J. Dean Zikria
- Headquarters
- San Antonio, TX
- Employees
- 52
- IPO year
- 2021
- Website
- valionbio.com
Financial highlights
Full financialsValion Bio reported a net loss of $8.9 million, compared with a loss of $5.7 million a year earlier.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | $780.00K | $1.18M | $1.84M | $1.26M |
| Growth | — | -33.67% | -36.09% | +46.38% | — |
| Net income | $-8.88M | $-5.66M | $-8.24M | $-10.10M | $-8.49M |
| EPS (diluted) | — | $-19.68 | $-176.80 | $-104.32 | $-2.43 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 20, 2026
- EPS actual vs est.
- $-49.25 vs —
VBIO news
All VBIO news- Tivic Health Systems, Inc. Stockholders Approve Reverse Stock Split Authority and 272,000 Share Increase to Equity Incentive PlanNasdaq
- Tivic Health Systems, Inc. Announces $700,000 Closing Under Series B Preferred Purchase AgreementNasdaq
- Tivic Health Systems, Inc. Enters Side Letters for $50,000 Series B and $4,717,717.61 Series C Preferred Stock ClosingsNasdaq
- Tivic Health Systems, Inc. Subsidiary Velocity Bioworks Receives Unsolicited Acquisition InterestNasdaq
- Tivic Health Systems, Inc. Interim CEO Dean Zikria Outlines Strategic Priorities and 30-Day AgendaNasdaq
Valion Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NXLNexalin Technology Inc. | 1.38 | -2.13% | $1.71M | vs VBIO |
| NUWENuwellis Inc. | 3.41 | -10.50% | $1.84M | vs VBIO |
| NDRAENDRA Life Sciences Inc. | 3.58 | -3.38% | $5.36M | vs VBIO |
| IRIXIRIDEX Corporation | 0.4449 | -4.59% | $7.92M | vs VBIO |
| ITOCiTonic Holdings Ltd Class A | 1.59 | +6.00% | $11.63M | vs VBIO |
| QTIQT Imaging Holdings Inc. | 1.92 | +2.67% | $28.21M | vs VBIO |
| ECORelectroCore Inc. | 4.42 | -8.87% | $40.78M | vs VBIO |
| POCIPrecision Optics Corporation Inc. | 4.12 | +1.41% | $45.30M | vs VBIO |
Indexes, lists and sector
Valion Bio stock FAQ
What is Valion Bio's stock price today?
VBIO last traded at $0.4806 as of Nov 20, 4:00 PM EST, down 10.98% on the day. Prices are delayed at least 15 minutes.
Who is Valion Bio's CEO?
Mr. J. Dean Zikria is the chief executive officer of Valion Bio Inc., which has about 52 employees.
What is the VBIO 52-week high?
The 52-week high for VBIO is $67.50 and the 52-week low is $0.472. The stock is currently 99.3% below its high.